CSIMarket Company Name, Ticker, Industry, else..
 
Vistagen Therapeutics Inc   (NASDAQ: VTGN)
 
Price: $0.2428 $-0.01 -2.880%
Day's High: $0.25839999318122864 Week Perf: -6.62 %
Day's Low: $ 0.24 30 Day Perf: -13.29 %
Volume (M): 346,802 52 Wk High: $ 5.14
Volume (M$): $ 0 52 Wk Avg: $1.49
Open: $0.25 52 Wk Low: $0.20



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 43
 Employees 41
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -68
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Business Description


Vistagen Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative therapies for mental health disorders. The company focuses on addressing the significant unmet medical needs in the field of psychiatry by utilizing a unique approach called pharmacological stress system modulation. Vistagen's aim is to develop safe and effective treatments for a variety of mental health conditions, including depression, anxiety, and substance use disorders. The company is dedicated to advancing the understanding of these disorders and improving the lives of patients through their cutting-edge therapeutic solutions.


   Company Address: 343 Allerton Avenue South San Francisco 94080 CA
   Company Phone Number: 577-3600   Stock Exchange / Ticker: NASDAQ VTGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -2.76%    
AXSM        3.85% 
BMRN        2.88% 
CLNN   -8.98%    
GOSS        3.12% 
PFE        1.75% 
• View Complete Report
   



Business Update

Vistagen’s Neuroscientific Surge Financial Acumen, Anxiety Insights, and Pioneering Pain Patent,

Published Mon, Nov 10 2025 3:17 PM UTC

: Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, continues to advance its neuroscience initiatives. With a focus on using nose-to-brain neurocircuitry, the company is developing intranasal product candidates known as pherines, targeting neurological and psychiatric conditions. Vistagen will disclose its fiscal year 2026 second-quarter financial r...
Business Update

Breakthrough Innovations in Neuropsychiatry Vistagen’s Advancements in Treating Social Anxiety Disorder with Pherines

Published Fri, May 23 2025 2:41 PM UTC

Recent developments in the field of neuropharmacology have opened new avenues for the treatment and understanding of psychiatric disorders, particularly social anxiety disorder (SAD). This article reviews the latest initiatives by Vistagen Theraputics (NASDAQ: VTGN), a clinical-stage biopharmaceutical firm that is pioneering nose-to-brain neurocircuitry to develop a unique c...
Business Update

Pioneering Intranasal Therapies Vistagens Innovative Approach to Social Anxiety Disorder Treatment,

Published Tue, Nov 5 2024 1:36 PM UTC

Exploring New Frontiers in the Treatment of Social Anxiety Disorder: Vistagen s Focus on Intranasal Pherine Therapies In the complex and evolving landscape of mental health treatment, Social Anxiety Disorder (SAD) remains a notable challenge, characterized by significant emotional distress stemming from public and social interactions. Recent discourse in the scientific commu...
Business Update

Vistagen Therapeutics Advancements in Neuroscience and Corporate Developments in Mental Health

Published Fri, Nov 1 2024 2:12 PM UTC

Vistagen Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, is actively engaged in the development of innovative therapies for psychiatric and neurological disorders. As part of its commitment to pioneering neuroscience applications, Vistagen utilizes nose-to-brain neurocircuitry to enhance drug delivery directly to the central nervous sys...
Business Update

Vistagen Launches Hopeful New Phase 3 Trial for Fasedienol A Game Changer in the Battle Against Social Anxiety D...

Published Mon, Sep 23 2024 1:47 PM UTC

In a significant advancement for mental health treatment, Vistagen Therapeutics, a neuroscience-focused biopharmaceutical company based in South San Francisco, has announced the commencement of its PALISADE-4 Phase 3 clinical trial for fasedienol. This investigational neuroactive pharmaceutical, delivered via nasal spray, aims to provide a new therapeutic option for individu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.17
Price to Sales (Expected) -
Price to Book 0.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.15
Working Capital Ratio 4.38
Leverage Ratio (MRQ) 0.46
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.59 $
Revenues (TTM) 0.06 $
Cash Flow (TTM) -
Cash 1.08 $
Book Value 0.57 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 61,000
Net Income per Employee (TTM) -1,649,268
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -904.34 %
Net Margin (MRQ) -882.79 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Vistagen Therapeutics Inc's Segments
License    13.55 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.